William David Dotson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6992086/publications.pdf

Version: 2024-02-01

31 papers 1,762 citations

304743 22 h-index 30 g-index

31 all docs

31 docs citations

31 times ranked 2701 citing authors

#	Article	IF	CITATIONS
1	The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group. Genetics in Medicine, 2009, 11, 3-14.	2.4	584
2	Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genetics in Medicine, 2009, 11, 21-34.	2.4	135
3	Delivery Of Cascade Screening For Hereditary Conditions: A Scoping Review Of The Literature. Health Affairs, 2018, 37, 801-808.	5.2	114
4	From public health genomics to precision public health: a 20-year journey. Genetics in Medicine, 2018, 20, 574-582.	2.4	109
5	Outcomes of interest in evidence-based evaluations of genetic tests. Genetics in Medicine, 2010, 12, 228-235.	2.4	82
6	Identification of a UPC2 Homolog in Saccharomyces cerevisiae and Its Involvement in Aerobic Sterol Uptake. Journal of Bacteriology, 2001, 183, 830-834.	2.2	56
7	Barriers and facilitators for cascade testing in genetic conditions: a systematic review. European Journal of Human Genetics, 2020, 28, 1631-1644.	2.8	55
8	Prioritizing Genomic Applications for Action by Level of Evidence: A Horizon-Scanning Method. Clinical Pharmacology and Therapeutics, 2014, 95, 394-402.	4.7	53
9	Beyond Base Pairs to Bedside: A Population Perspective on How Genomics Can Improve Health. American Journal of Public Health, 2012, 102, 34-37.	2.7	51
10	Public Awareness of Genetic Nondiscrimination Laws in Four States and Perceived Importance of Life Insurance Protections. Journal of Genetic Counseling, 2015, 24, 512-521.	1.6	47
11	Trends in utilization and costs of BRCA testing among women aged 18–64 years in the United States, 2003–2014. Genetics in Medicine, 2018, 20, 428-434.	2.4	42
12	Horizon scanning for new genomic tests. Genetics in Medicine, 2011, 13, 161-165.	2.4	39
13	Cost-Effectiveness of Risk-Stratified Colorectal Cancer Screening Based on Polygenic Risk: Current Status and Future Potential. JNCI Cancer Spectrum, 2020, 4, pkz086.	2.9	39
14	Health equity in the implementation of genomics and precision medicine: A public health imperative. Genetics in Medicine, 2022, 24, 1630-1639.	2.4	38
15	<i>BRCA</i> Genetic Testing and Receipt of Preventive Interventions Among Women Aged 18–64 Years with Employer-Sponsored Health Insurance in Nonmetropolitan and Metropolitan Areas — United States, 2009–2014. MMWR Surveillance Summaries, 2017, 66, 1-11.	34.6	33
16	Use of genomic profiling to assess risk for cardiovascular disease and identify individualized prevention strategies—A targeted evidence-based review. Genetics in Medicine, 2010, 12, 772-784.	2.4	32
17	Utilization of genetic tests: analysis of gene-specific billing in Medicare claims data. Genetics in Medicine, 2017, 19, 890-899.	2.4	31
18	Evaluating the role of public health in implementation of genomics-related recommendations: a case study of hereditary cancers using the CDC Science Impact Framework. Genetics in Medicine, 2019, 21, 28-37.	2.4	31

#	Article	IF	CITATIONS
19	Horizon scanning for translational genomic research beyond bench to bedside. Genetics in Medicine, 2014, 16, 535-538.	2.4	28
20	Knowledge integration at the center of genomic medicine. Genetics in Medicine, 2012, 14, 643-647.	2.4	26
21	Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews. Genetics in Medicine, 2015, 17, 519-532.	2.4	26
22	Genomics in Public Health: Perspective from the Office of Public Health Genomics at the Centers for Disease Control and Prevention (CDC). Healthcare (Switzerland), 2015, 3, 830-837.	2.0	25
23	A knowledge base for tracking the impact of genomics on population health. Genetics in Medicine, 2016, 18, 1312-1314.	2.4	17
24	Evidence synthesis and guideline development in genomic medicine: current status and future prospects. Genetics in Medicine, 2015, 17, 63-67.	2.4	16
25	Clinical utility of genetic and genomic services: context matters. Genetics in Medicine, 2016, 18, 672-674.	2.4	15
26	Is there a need for PGxceptionalism?. Genetics in Medicine, 2011, 13, 866-867.	2.4	13
27	From genes to public health: are we ready for DNA-based population screening?. Genetics in Medicine, 2021, 23, 996-998.	2.4	12
28	PLoS Currents: Evidence on Genomic Tests – At the Crossroads of Translation. PLOS Currents, 2010, 2, RRN1179.	1.4	6
29	Challenges and Opportunities for Communication about the Role of Genomics in Public Health. Public Health Genomics, 2021, 24, 67-74.	1.0	3
30	The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group., 2009,, 458-481.		3
31	Tumor Gene Expression Profiling in Women with Breast CancerTest Category: Prognostic. PLOS Currents, 2010, 2, RRN1178.	1.4	1